LANTHEUS HOLDINGS, INC. (NASDAQ:LNTH) Files An 8-K Other Events
Item 8.01.
On November 7, 2019, Lantheus Holdings, Inc. issued a press release relating to its pending acquisition of Progenics Pharmaceuticals, Inc. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.
(d) Exhibits
| 99.1 | Press release of Lantheus Holdings, Inc. dated November 7, 2019 |
Lantheus Holdings, Inc. Exhibit
EX-99.1 2 d805232dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Lantheus Releases Comprehensive Strategic Plan for Progenics Lantheus’ Value-Creating Vision for Integrating and Executing Transaction is Best Path Forward for Progenics Lantheus’ In-Place Infrastructure and Commercial Capabilities Will Ensure the Progress of AZEDRA,…
To view the full exhibit click here
About LANTHEUS HOLDINGS, INC. (NASDAQ:LNTH)
Lantheus Holdings, Inc. develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company’s Contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.
